SI-Bone price target lowered to $18 from $20 at Truist

Truist analyst Samuel Brodovsky lowered the firm’s price target on SI-Bone to $18 from $20 and keeps a Buy rating on the shares. SI-Bone posted a slight Q2 beat and raise with EBITDA outperformance, and Truist thinks there could be conservatism to the guide and that SI-Bone is set up to continue to beat & raise through the second half, the analyst tells investors in a research note. The firm likes the setup for 2025 with new product cycles that should help support leave upside to the high-teens growth profile.